Nothing Special   »   [go: up one dir, main page]

EP1356079A4 - Srebp pathway modulation through targeting hisrs - Google Patents

Srebp pathway modulation through targeting hisrs

Info

Publication number
EP1356079A4
EP1356079A4 EP02713405A EP02713405A EP1356079A4 EP 1356079 A4 EP1356079 A4 EP 1356079A4 EP 02713405 A EP02713405 A EP 02713405A EP 02713405 A EP02713405 A EP 02713405A EP 1356079 A4 EP1356079 A4 EP 1356079A4
Authority
EP
European Patent Office
Prior art keywords
hisrs
targeting
srebp pathway
pathway modulation
modulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02713405A
Other languages
German (de)
French (fr)
Other versions
EP1356079A2 (en
Inventor
Cynthia Seidel-Dugan
Lisa C Kadyk
Felipa A Mapa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of EP1356079A2 publication Critical patent/EP1356079A2/en
Publication of EP1356079A4 publication Critical patent/EP1356079A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93Ligases (6)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Emergency Medicine (AREA)
EP02713405A 2001-01-12 2002-01-11 Srebp pathway modulation through targeting hisrs Withdrawn EP1356079A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26156901P 2001-01-12 2001-01-12
US261569P 2001-01-12
PCT/US2002/001045 WO2002055663A2 (en) 2001-01-12 2002-01-11 Srebp pathway modulation through targeting hisrs

Publications (2)

Publication Number Publication Date
EP1356079A2 EP1356079A2 (en) 2003-10-29
EP1356079A4 true EP1356079A4 (en) 2005-10-19

Family

ID=22993896

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02713405A Withdrawn EP1356079A4 (en) 2001-01-12 2002-01-11 Srebp pathway modulation through targeting hisrs

Country Status (4)

Country Link
EP (1) EP1356079A4 (en)
JP (1) JP2004524021A (en)
AU (1) AU2002245257A1 (en)
WO (1) WO2002055663A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010013632A (en) 2008-06-11 2011-06-16 Atyr Pharma Inc Thrombopoietic activity of tyrosyl-trna synthetase polypeptides.
CN106434576A (en) 2008-06-26 2017-02-22 Atyr 医药公司 Compositions and methods comprising glycyl-trna synthetases having non-canonical biological activities
EP2403864B1 (en) 2009-02-27 2015-08-12 Atyr Pharma, Inc. Polypeptide structural motifs associated with cell signaling activity
CN104830812B (en) 2009-03-16 2017-09-05 盘古生物制药有限公司 Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities
US20100310576A1 (en) 2009-03-31 2010-12-09 Adams Ryan A COMPOSITIONS AND METHODS COMPRISING ASPARTYL-tRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES
US8828395B2 (en) 2009-12-11 2014-09-09 Atyr Pharma, Inc. Antibodies that bind tyrosyl-tRNA synthetases
CA2783731C (en) 2009-12-11 2018-03-27 Atyr Pharma, Inc. Aminoacyl trna synthetases for modulating inflammation
CN103118695B (en) 2010-07-12 2016-08-03 Atyr医药公司 The discovery for the treatment of, diagnosis and the antibody compositions relevant to the protein fragments of Glycyl-tRNA synthetase
EP2593126B1 (en) 2010-07-12 2017-09-20 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases
US8969301B2 (en) 2010-07-12 2015-03-03 Atyr Pharma Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-tRNA synthetases
US8999321B2 (en) 2010-07-12 2015-04-07 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
WO2012027611A2 (en) 2010-08-25 2012-03-01 Atyr Pharma, Inc. INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF TYROSYL-tRNA SYNTHETASES
WO2013022982A2 (en) 2011-08-09 2013-02-14 Atyr Pharma, Inc. Pegylated tyrosyl-trna synthetase polypeptides
US9822353B2 (en) 2011-12-06 2017-11-21 Atyr Pharma, Inc. PEGylated aspartyl-tRNA synthetase polypeptides
WO2013086216A1 (en) 2011-12-06 2013-06-13 Atyr Pharma, Inc. Improved aspartyl-trna synthetases
WO2013115926A2 (en) 2011-12-29 2013-08-08 Atyr Pharma, Inc. Aspartyl-trna synthetase-fc conjugates
US8835387B2 (en) 2012-02-16 2014-09-16 Atyr Pharma, Inc. Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
EP3460054B1 (en) 2013-03-15 2020-10-21 aTyr Pharma, Inc. Histidyl-trna synthetase-fc conjugates
WO2015027171A1 (en) * 2013-08-23 2015-02-26 Quintiles Transnational Corporation Methods for predicting toxicity in response to treatment with a drug by assessing activation of the sterol regulatory binding protein (srebp) pathway
DK3612215T3 (en) 2017-04-20 2024-10-28 Atyr Pharma Inc COMPOSITIONS FOR THE TREATMENT OF PULMONARY INFLAMMATION

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076308A1 (en) * 1999-06-14 2000-12-21 Exelixis, Inc. Animal models and methods for analysis of lipid metabolism and screening of pharmaceutical and pesticidal agents that modulate lipid metabolism

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076308A1 (en) * 1999-06-14 2000-12-21 Exelixis, Inc. Animal models and methods for analysis of lipid metabolism and screening of pharmaceutical and pesticidal agents that modulate lipid metabolism

Also Published As

Publication number Publication date
JP2004524021A (en) 2004-08-12
EP1356079A2 (en) 2003-10-29
WO2002055663A3 (en) 2002-09-19
AU2002245257A1 (en) 2002-07-24
WO2002055663A2 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
EP1356079A4 (en) Srebp pathway modulation through targeting hisrs
EP1443963A4 (en) Antibody targeting compounds
SG102048A1 (en) Fridge-freezer
IL157374A0 (en) Capsule
EP1446418A4 (en) Integrin targeting compounds
EP1420747A4 (en) Benzoquinone ansamycins
EP1377187A4 (en) An improved backpack
EP1463127A4 (en) Photodiode
GB0119665D0 (en) Conjugates
HUP0105406D0 (en) Ovel compounds
TW584302U (en) Center-adjustment assembling device
EP1392204A4 (en) Bifunctional energy-reversible acyl-compositions
GB0103763D0 (en) Pak-Gep Construct
HK1054850A1 (en) Walker
GB0124150D0 (en) Housing
AU143630S (en) Rodent baitstation assembly
GB2382025B (en) Balanced non-swerve castor
AU3099P (en) Gan01 Cordyline fruticosa
AU2634P (en) Darzing Pinelime Zingiber spectabile
IL146586A0 (en) Orthopedic targeting device
GB0123748D0 (en) Laser field
GB0126806D0 (en) Modulation
GB0126808D0 (en) Modulation
GB0126771D0 (en) Modulation
GB0119100D0 (en) Functional polyaromatic polymers

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030731

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050905

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 48/00 B

Ipc: 7A 61K 39/00 B

Ipc: 7C 12Q 1/25 B

Ipc: 7G 01N 33/92 A

17Q First examination report despatched

Effective date: 20051206

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070731